Get to know our clinical trials
Clinical trial of THOR-707 dosing in monotherapy and as combination therapy in adult subjects with advanced or metastatic solid tumors.
THE PRIMARY OBJECTIVE IS TO ASSESS THE SAFETY AND TOLERABILITY OF THOR-707 IN MONOTHERAPY AND AS COMBINATION THERAPY (IDENTIFY TLD [EXCEPT COHORTS H, E AND F], AA PROFILE/SERIOUS ADVERSE EVENTS) (EXCEPT COHORT H) &IQUEST; DEFINE THE TLD AND/OR DRF2 OF THOR-707 IN MONOTHERAPY AND AS COMBINATION THERAPY (FOR PART 1 AND PART 2 ONLY). &IQUEST; EVALUATE THE PRELIMINARY ANTITUMOR ACTIVITY OF THOR-707 IN MONOTHERAPY BY DETERMINING THE OBJECTIVE RESPONSE RATE (ORR) DEFINED ACCORDING TO THE RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST), VERSION 1.1 (COHORT H ONLY).
- Code EudraCT: Not applicable
- Protocol number: THOR-707-101
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.